Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

“Zynerba is committed to developing Zygel™ CBD gel

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
dhbuzz Member Profile
 
Followed By 9
Posts 2,775
Boards Moderated 0
Alias Born 03/01/19
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/8/2021 1:05:46 PM
Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences GlobeNewswire Inc. - 1/4/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2020 7:02:09 AM
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome GlobeNewswire Inc. - 12/17/2020 6:30:00 AM
Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc. Business Wire - 12/9/2020 3:49:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/4/2020 12:31:08 PM
Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES) GlobeNewswire Inc. - 12/4/2020 11:30:00 AM
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy S... GlobeNewswire Inc. - 11/23/2020 11:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2020 7:17:39 AM
Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights GlobeNewswire Inc. - 11/9/2020 6:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2020 4:16:27 PM
Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the... GlobeNewswire Inc. - 10/15/2020 3:06:10 PM
New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder... GlobeNewswire Inc. - 10/15/2020 3:05:10 PM
Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACA... GlobeNewswire Inc. - 10/8/2020 8:32:10 AM
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16... GlobeNewswire Inc. - 10/8/2020 8:30:10 AM
Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome GlobeNewswire Inc. - 9/17/2020 1:55:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/14/2020 7:02:02 AM
Zynerba Pharmaceuticals Provides Update on Recent Milestones GlobeNewswire Inc. - 9/14/2020 6:55:10 AM
Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences GlobeNewswire Inc. - 9/10/2020 7:30:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 9:28:55 AM
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights GlobeNewswire Inc. - 8/10/2020 6:45:10 AM
Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference GlobeNewswire Inc. - 8/6/2020 7:00:10 AM
Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Con... GlobeNewswire Inc. - 7/22/2020 6:50:10 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2020 10:43:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/30/2020 6:59:54 AM
dhbuzz   Saturday, 09/19/20 12:19:26 PM
Re: dhbuzz post# 2600
Post # of 2640 
“Zynerba is committed to developing Zygel™ CBD gel in certain rare and near-rare conditions, including 22q, for which there is an urgent need for new, innovative therapeutics,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “We are pleased that the FDA shares our sense of urgency regarding the development of effective therapeutics in this important patient population. The receipt of this designation represents another important milestone for us, and we look forward to working closely with the FDA to develop Zygel in pediatric and adolescent patients with 22q as expeditiously as possible.”

About Orphan Drug Designation
Under the Orphan Drug Act (ODA), the FDA may grant orphan drug designation to drugs intended to treat rare diseases or conditions that affect fewer than 200,000 individuals in the U.S. The first NDA applicant to receive FDA approval for a particular active moiety to treat a particular disease with FDA orphan drug designation is entitled to various incentives of the ODA, including tax credits for qualified clinical testing, waiver of new drug application (NDA) / biologics license application (BLA) user fees, and eligibility for a seven-year exclusive marketing period for that drug and use upon marketing approval.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences